: Aim: To validate a 'drug score' that stratifies patients receiving immunotherapy based on concomitant medications (antibiotics/proton pump inhibitors/corticosteroids) in urothelial carcinoma (UC). Materials & methods: We assessed oncological outcomes according to the drug score in 242 patients with advanced UC treated with pembrolizumab. Results: The drug score classified patients into three risk groups with significantly different survivals. Heterogeneous treatment effect analyses showed that the primary cancer site (bladder UC [BUC] or upper-tract UC [UTUC]) significantly affected the prognostic capability of the drug score; it significantly correlated with survivals in BUC, while there were no such correlations in UTUC. Conclusion: A drug score was examined in advanced UC treated with pembrolizumab and was validated in BUC but not in UTUC.
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab / Taguchi, Satoru; Kawai, Taketo; Buti, Sebastiano; Bersanelli, Melissa; Uemura, Yukari; Kishitani, Kenjiro; Miyakawa, Jimpei; Sugimoto, Kazuma; Nakamura, Yu; Niimi, Fusako; Kaneko, Tomoyuki; Kamei, Jun; Obinata, Daisuke; Yamaguchi, Kenya; Kakutani, Shigenori; Kanazawa, Koichiro; Sugihara, Yuriko; Tokunaga, Mayuko; Akiyama, Yoshiyuki; Yamada, Yuta; Sato, Yusuke; Yamada, Daisuke; Enomoto, Yutaka; Nishimatsu, Hiroaki; Fujimura, Tetsuya; Fukuhara, Hiroshi; Nakagawa, Tohru; Takahashi, Satoru; Kume, Haruki. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - (2023). [10.2217/imt-2023-0028]
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab
Buti, SebastianoConceptualization
;Bersanelli, Melissa;
2023-01-01
Abstract
: Aim: To validate a 'drug score' that stratifies patients receiving immunotherapy based on concomitant medications (antibiotics/proton pump inhibitors/corticosteroids) in urothelial carcinoma (UC). Materials & methods: We assessed oncological outcomes according to the drug score in 242 patients with advanced UC treated with pembrolizumab. Results: The drug score classified patients into three risk groups with significantly different survivals. Heterogeneous treatment effect analyses showed that the primary cancer site (bladder UC [BUC] or upper-tract UC [UTUC]) significantly affected the prognostic capability of the drug score; it significantly correlated with survivals in BUC, while there were no such correlations in UTUC. Conclusion: A drug score was examined in advanced UC treated with pembrolizumab and was validated in BUC but not in UTUC.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
